{"id":"insulin-rinsulin-nph","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin formulation created by complexing insulin with protamine, which slows its absorption and extends its duration of action to 10-16 hours. It works by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. Rinsulin® NPH is a biosynthetic human insulin product manufactured by Geropharm.","oneSentence":"Insulin NPH is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:37.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04501250","phase":"NA","title":"Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-10-23","conditions":"Pharmacokinetics, Bioequivalence","enrollment":52},{"nctId":"NCT04012775","phase":"PHASE3","title":"Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-20","conditions":"Diabetes Mellitus, Type 2","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin Rinsulin® NPH","genericName":"Insulin Rinsulin® NPH","companyName":"Geropharm","companyId":"geropharm","modality":"Biologic","firstApprovalDate":"","aiSummary":"Insulin NPH is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}